In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 375 of 392

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	TBC
Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment	Health technology evaluation	22 May 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]	Technology appraisal guidance	TBC
Transcatheter aortic valve implantation for native aortic valve regurgitation	Interventional procedures guidance	11 June 2025
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment	Health technology evaluation	8 January 2025
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia	Interventional procedures guidance	8 January 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	10 September 2025
Treatments for non-small-cell lung cancer [ID6234]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891	Technology appraisal guidance	TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	19 June 2025
Ublituximab for treating relapsing multiple sclerosis [ID6350]	Technology appraisal guidance	TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]	Technology appraisal guidance	TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing	NICE guideline	12 December 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]	Technology appraisal guidance	8 January 2025
Vamorolone for treating Duchenne muscular dystrophy [ID4024]	Technology appraisal guidance	TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]	Technology appraisal guidance	TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]	Technology appraisal guidance	TBC

Results per page

10
25
50
All